nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—Blood creatinine increased—Epirubicin—uterine cancer	0.000918	0.000927	CcSEcCtD
Acamprosate—Convulsion—Etoposide—uterine cancer	0.000912	0.000921	CcSEcCtD
Acamprosate—Hyponatraemia—Doxorubicin—uterine cancer	0.00091	0.000919	CcSEcCtD
Acamprosate—Hypertension—Etoposide—uterine cancer	0.000909	0.000918	CcSEcCtD
Acamprosate—Diplopia—Doxorubicin—uterine cancer	0.000907	0.000915	CcSEcCtD
Acamprosate—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000907	0.000915	CcSEcCtD
Acamprosate—Liver function test abnormal—Epirubicin—uterine cancer	0.000905	0.000913	CcSEcCtD
Acamprosate—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000904	0.000913	CcSEcCtD
Acamprosate—Dry skin—Epirubicin—uterine cancer	0.000898	0.000907	CcSEcCtD
Acamprosate—Chest pain—Etoposide—uterine cancer	0.000896	0.000905	CcSEcCtD
Acamprosate—Orthostatic hypotension—Epirubicin—uterine cancer	0.000895	0.000904	CcSEcCtD
Acamprosate—Migraine—Doxorubicin—uterine cancer	0.000892	0.000901	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.00089	0.000899	CcSEcCtD
Acamprosate—Discomfort—Etoposide—uterine cancer	0.000885	0.000894	CcSEcCtD
Acamprosate—Breast disorder—Epirubicin—uterine cancer	0.000885	0.000894	CcSEcCtD
Acamprosate—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000882	0.000891	CcSEcCtD
Acamprosate—Face oedema—Doxorubicin—uterine cancer	0.000875	0.000884	CcSEcCtD
Acamprosate—Hypersensitivity—Dactinomycin—uterine cancer	0.000875	0.000883	CcSEcCtD
Acamprosate—Gastritis—Epirubicin—uterine cancer	0.000867	0.000876	CcSEcCtD
Acamprosate—Confusional state—Etoposide—uterine cancer	0.000866	0.000875	CcSEcCtD
Acamprosate—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000864	0.000873	CcSEcCtD
Acamprosate—Anaphylactic shock—Etoposide—uterine cancer	0.000859	0.000867	CcSEcCtD
Acamprosate—Infection—Etoposide—uterine cancer	0.000854	0.000862	CcSEcCtD
Acamprosate—Abdominal distension—Epirubicin—uterine cancer	0.000853	0.000861	CcSEcCtD
Acamprosate—Asthenia—Dactinomycin—uterine cancer	0.000852	0.00086	CcSEcCtD
Acamprosate—Blood creatinine increased—Doxorubicin—uterine cancer	0.000849	0.000858	CcSEcCtD
Acamprosate—Dysphagia—Epirubicin—uterine cancer	0.000847	0.000855	CcSEcCtD
Acamprosate—Asthma—Epirubicin—uterine cancer	0.000847	0.000855	CcSEcCtD
Acamprosate—Influenza—Epirubicin—uterine cancer	0.000847	0.000855	CcSEcCtD
Acamprosate—Thrombocytopenia—Etoposide—uterine cancer	0.000841	0.000849	CcSEcCtD
Acamprosate—Tachycardia—Etoposide—uterine cancer	0.000839	0.000847	CcSEcCtD
Acamprosate—Eosinophilia—Epirubicin—uterine cancer	0.000839	0.000847	CcSEcCtD
Acamprosate—Liver function test abnormal—Doxorubicin—uterine cancer	0.000837	0.000845	CcSEcCtD
Acamprosate—Skin disorder—Etoposide—uterine cancer	0.000835	0.000843	CcSEcCtD
Acamprosate—Dry skin—Doxorubicin—uterine cancer	0.000831	0.000839	CcSEcCtD
Acamprosate—Hyperhidrosis—Etoposide—uterine cancer	0.000831	0.000839	CcSEcCtD
Acamprosate—Pancreatitis—Epirubicin—uterine cancer	0.00083	0.000838	CcSEcCtD
Acamprosate—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000828	0.000836	CcSEcCtD
Acamprosate—Angina pectoris—Epirubicin—uterine cancer	0.000825	0.000833	CcSEcCtD
Acamprosate—Breast disorder—Doxorubicin—uterine cancer	0.000819	0.000827	CcSEcCtD
Acamprosate—Anorexia—Etoposide—uterine cancer	0.000819	0.000827	CcSEcCtD
Acamprosate—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000816	0.000824	CcSEcCtD
Acamprosate—Bronchitis—Epirubicin—uterine cancer	0.000814	0.000822	CcSEcCtD
Acamprosate—Diarrhoea—Dactinomycin—uterine cancer	0.000812	0.00082	CcSEcCtD
Acamprosate—Hypotension—Etoposide—uterine cancer	0.000803	0.000811	CcSEcCtD
Acamprosate—Gastritis—Doxorubicin—uterine cancer	0.000802	0.00081	CcSEcCtD
Acamprosate—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.0008	0.000807	CcSEcCtD
Acamprosate—Abdominal distension—Doxorubicin—uterine cancer	0.000789	0.000796	CcSEcCtD
Acamprosate—Influenza—Doxorubicin—uterine cancer	0.000784	0.000791	CcSEcCtD
Acamprosate—Asthma—Doxorubicin—uterine cancer	0.000784	0.000791	CcSEcCtD
Acamprosate—Dysphagia—Doxorubicin—uterine cancer	0.000784	0.000791	CcSEcCtD
Acamprosate—Pollakiuria—Epirubicin—uterine cancer	0.000782	0.00079	CcSEcCtD
Acamprosate—Eosinophilia—Doxorubicin—uterine cancer	0.000776	0.000783	CcSEcCtD
Acamprosate—Photosensitivity reaction—Epirubicin—uterine cancer	0.000773	0.00078	CcSEcCtD
Acamprosate—Paraesthesia—Etoposide—uterine cancer	0.000771	0.000779	CcSEcCtD
Acamprosate—Weight increased—Epirubicin—uterine cancer	0.000771	0.000778	CcSEcCtD
Acamprosate—Pancreatitis—Doxorubicin—uterine cancer	0.000768	0.000776	CcSEcCtD
Acamprosate—Weight decreased—Epirubicin—uterine cancer	0.000766	0.000774	CcSEcCtD
Acamprosate—Dyspnoea—Etoposide—uterine cancer	0.000766	0.000773	CcSEcCtD
Acamprosate—Hyperglycaemia—Epirubicin—uterine cancer	0.000764	0.000771	CcSEcCtD
Acamprosate—Somnolence—Etoposide—uterine cancer	0.000764	0.000771	CcSEcCtD
Acamprosate—Angina pectoris—Doxorubicin—uterine cancer	0.000763	0.000771	CcSEcCtD
Acamprosate—Pneumonia—Epirubicin—uterine cancer	0.000759	0.000767	CcSEcCtD
Acamprosate—Vomiting—Dactinomycin—uterine cancer	0.000755	0.000762	CcSEcCtD
Acamprosate—Bronchitis—Doxorubicin—uterine cancer	0.000754	0.000761	CcSEcCtD
Acamprosate—Rash—Dactinomycin—uterine cancer	0.000748	0.000756	CcSEcCtD
Acamprosate—Decreased appetite—Etoposide—uterine cancer	0.000747	0.000754	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Etoposide—uterine cancer	0.000742	0.000749	CcSEcCtD
Acamprosate—Stomatitis—Epirubicin—uterine cancer	0.000736	0.000743	CcSEcCtD
Acamprosate—Pain—Etoposide—uterine cancer	0.000735	0.000742	CcSEcCtD
Acamprosate—Constipation—Etoposide—uterine cancer	0.000735	0.000742	CcSEcCtD
Acamprosate—Urinary tract infection—Epirubicin—uterine cancer	0.000734	0.000741	CcSEcCtD
Acamprosate—Sweating—Epirubicin—uterine cancer	0.000724	0.000731	CcSEcCtD
Acamprosate—Pollakiuria—Doxorubicin—uterine cancer	0.000724	0.000731	CcSEcCtD
Acamprosate—Haematuria—Epirubicin—uterine cancer	0.00072	0.000727	CcSEcCtD
Acamprosate—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000715	0.000722	CcSEcCtD
Acamprosate—Weight increased—Doxorubicin—uterine cancer	0.000713	0.00072	CcSEcCtD
Acamprosate—Epistaxis—Epirubicin—uterine cancer	0.000712	0.000719	CcSEcCtD
Acamprosate—Weight decreased—Doxorubicin—uterine cancer	0.000709	0.000716	CcSEcCtD
Acamprosate—Feeling abnormal—Etoposide—uterine cancer	0.000708	0.000715	CcSEcCtD
Acamprosate—Hyperglycaemia—Doxorubicin—uterine cancer	0.000707	0.000714	CcSEcCtD
Acamprosate—Nausea—Dactinomycin—uterine cancer	0.000705	0.000712	CcSEcCtD
Acamprosate—Pneumonia—Doxorubicin—uterine cancer	0.000703	0.00071	CcSEcCtD
Acamprosate—Gastrointestinal pain—Etoposide—uterine cancer	0.000703	0.000709	CcSEcCtD
Acamprosate—Urticaria—Etoposide—uterine cancer	0.000683	0.000689	CcSEcCtD
Acamprosate—Haemoglobin—Epirubicin—uterine cancer	0.000681	0.000688	CcSEcCtD
Acamprosate—Stomatitis—Doxorubicin—uterine cancer	0.000681	0.000688	CcSEcCtD
Acamprosate—Rhinitis—Epirubicin—uterine cancer	0.00068	0.000686	CcSEcCtD
Acamprosate—Abdominal pain—Etoposide—uterine cancer	0.000679	0.000686	CcSEcCtD
Acamprosate—Body temperature increased—Etoposide—uterine cancer	0.000679	0.000686	CcSEcCtD
Acamprosate—Urinary tract infection—Doxorubicin—uterine cancer	0.000679	0.000686	CcSEcCtD
Acamprosate—Hepatitis—Epirubicin—uterine cancer	0.000678	0.000684	CcSEcCtD
Acamprosate—Haemorrhage—Epirubicin—uterine cancer	0.000678	0.000684	CcSEcCtD
Acamprosate—Hypoaesthesia—Epirubicin—uterine cancer	0.000674	0.000681	CcSEcCtD
Acamprosate—Pharyngitis—Epirubicin—uterine cancer	0.000673	0.000679	CcSEcCtD
Acamprosate—Sweating—Doxorubicin—uterine cancer	0.00067	0.000676	CcSEcCtD
Acamprosate—Oedema peripheral—Epirubicin—uterine cancer	0.000668	0.000674	CcSEcCtD
Acamprosate—Haematuria—Doxorubicin—uterine cancer	0.000666	0.000673	CcSEcCtD
Acamprosate—Epistaxis—Doxorubicin—uterine cancer	0.000659	0.000665	CcSEcCtD
Acamprosate—Visual impairment—Epirubicin—uterine cancer	0.000653	0.00066	CcSEcCtD
Acamprosate—Hypersensitivity—Etoposide—uterine cancer	0.000633	0.000639	CcSEcCtD
Acamprosate—Tinnitus—Epirubicin—uterine cancer	0.000632	0.000638	CcSEcCtD
Acamprosate—Haemoglobin—Doxorubicin—uterine cancer	0.00063	0.000636	CcSEcCtD
Acamprosate—Rhinitis—Doxorubicin—uterine cancer	0.000629	0.000635	CcSEcCtD
Acamprosate—Hepatitis—Doxorubicin—uterine cancer	0.000627	0.000633	CcSEcCtD
Acamprosate—Haemorrhage—Doxorubicin—uterine cancer	0.000627	0.000633	CcSEcCtD
Acamprosate—Hypoaesthesia—Doxorubicin—uterine cancer	0.000624	0.00063	CcSEcCtD
Acamprosate—Pharyngitis—Doxorubicin—uterine cancer	0.000623	0.000629	CcSEcCtD
Acamprosate—Oedema peripheral—Doxorubicin—uterine cancer	0.000618	0.000624	CcSEcCtD
Acamprosate—Asthenia—Etoposide—uterine cancer	0.000616	0.000622	CcSEcCtD
Acamprosate—Immune system disorder—Epirubicin—uterine cancer	0.000612	0.000618	CcSEcCtD
Acamprosate—Chills—Epirubicin—uterine cancer	0.000608	0.000614	CcSEcCtD
Acamprosate—Pruritus—Etoposide—uterine cancer	0.000608	0.000614	CcSEcCtD
Acamprosate—Visual impairment—Doxorubicin—uterine cancer	0.000604	0.00061	CcSEcCtD
Acamprosate—Alopecia—Epirubicin—uterine cancer	0.000599	0.000605	CcSEcCtD
Acamprosate—Mental disorder—Epirubicin—uterine cancer	0.000594	0.0006	CcSEcCtD
Acamprosate—Malnutrition—Epirubicin—uterine cancer	0.00059	0.000596	CcSEcCtD
Acamprosate—Diarrhoea—Etoposide—uterine cancer	0.000588	0.000594	CcSEcCtD
Acamprosate—Tinnitus—Doxorubicin—uterine cancer	0.000585	0.00059	CcSEcCtD
Acamprosate—Flatulence—Epirubicin—uterine cancer	0.000581	0.000587	CcSEcCtD
Acamprosate—Tension—Epirubicin—uterine cancer	0.000579	0.000585	CcSEcCtD
Acamprosate—Dysgeusia—Epirubicin—uterine cancer	0.000578	0.000583	CcSEcCtD
Acamprosate—Nervousness—Epirubicin—uterine cancer	0.000573	0.000579	CcSEcCtD
Acamprosate—Back pain—Epirubicin—uterine cancer	0.000571	0.000576	CcSEcCtD
Acamprosate—Dizziness—Etoposide—uterine cancer	0.000568	0.000574	CcSEcCtD
Acamprosate—Muscle spasms—Epirubicin—uterine cancer	0.000567	0.000573	CcSEcCtD
Acamprosate—Immune system disorder—Doxorubicin—uterine cancer	0.000567	0.000572	CcSEcCtD
Acamprosate—Chills—Doxorubicin—uterine cancer	0.000563	0.000568	CcSEcCtD
Acamprosate—Alopecia—Doxorubicin—uterine cancer	0.000554	0.00056	CcSEcCtD
Acamprosate—Mental disorder—Doxorubicin—uterine cancer	0.000549	0.000555	CcSEcCtD
Acamprosate—Ill-defined disorder—Epirubicin—uterine cancer	0.000548	0.000553	CcSEcCtD
Acamprosate—Vomiting—Etoposide—uterine cancer	0.000546	0.000552	CcSEcCtD
Acamprosate—Malnutrition—Doxorubicin—uterine cancer	0.000546	0.000551	CcSEcCtD
Acamprosate—Anaemia—Epirubicin—uterine cancer	0.000545	0.000551	CcSEcCtD
Acamprosate—Agitation—Epirubicin—uterine cancer	0.000542	0.000548	CcSEcCtD
Acamprosate—Rash—Etoposide—uterine cancer	0.000542	0.000547	CcSEcCtD
Acamprosate—Dermatitis—Etoposide—uterine cancer	0.000541	0.000546	CcSEcCtD
Acamprosate—Headache—Etoposide—uterine cancer	0.000538	0.000543	CcSEcCtD
Acamprosate—Flatulence—Doxorubicin—uterine cancer	0.000538	0.000543	CcSEcCtD
Acamprosate—Tension—Doxorubicin—uterine cancer	0.000536	0.000541	CcSEcCtD
Acamprosate—Dysgeusia—Doxorubicin—uterine cancer	0.000535	0.00054	CcSEcCtD
Acamprosate—Malaise—Epirubicin—uterine cancer	0.000532	0.000537	CcSEcCtD
Acamprosate—Nervousness—Doxorubicin—uterine cancer	0.00053	0.000535	CcSEcCtD
Acamprosate—Vertigo—Epirubicin—uterine cancer	0.00053	0.000535	CcSEcCtD
Acamprosate—Syncope—Epirubicin—uterine cancer	0.000529	0.000534	CcSEcCtD
Acamprosate—Leukopenia—Epirubicin—uterine cancer	0.000528	0.000533	CcSEcCtD
Acamprosate—Back pain—Doxorubicin—uterine cancer	0.000528	0.000533	CcSEcCtD
Acamprosate—Muscle spasms—Doxorubicin—uterine cancer	0.000525	0.00053	CcSEcCtD
Acamprosate—Palpitations—Epirubicin—uterine cancer	0.000521	0.000526	CcSEcCtD
Acamprosate—Loss of consciousness—Epirubicin—uterine cancer	0.000519	0.000524	CcSEcCtD
Acamprosate—Cough—Epirubicin—uterine cancer	0.000515	0.00052	CcSEcCtD
Acamprosate—Convulsion—Epirubicin—uterine cancer	0.000511	0.000516	CcSEcCtD
Acamprosate—Nausea—Etoposide—uterine cancer	0.00051	0.000515	CcSEcCtD
Acamprosate—Hypertension—Epirubicin—uterine cancer	0.000509	0.000514	CcSEcCtD
Acamprosate—Ill-defined disorder—Doxorubicin—uterine cancer	0.000507	0.000511	CcSEcCtD
Acamprosate—Anaemia—Doxorubicin—uterine cancer	0.000505	0.00051	CcSEcCtD
Acamprosate—Chest pain—Epirubicin—uterine cancer	0.000502	0.000507	CcSEcCtD
Acamprosate—Arthralgia—Epirubicin—uterine cancer	0.000502	0.000507	CcSEcCtD
Acamprosate—Myalgia—Epirubicin—uterine cancer	0.000502	0.000507	CcSEcCtD
Acamprosate—Agitation—Doxorubicin—uterine cancer	0.000502	0.000507	CcSEcCtD
Acamprosate—Anxiety—Epirubicin—uterine cancer	0.000501	0.000505	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000499	0.000504	CcSEcCtD
Acamprosate—Discomfort—Epirubicin—uterine cancer	0.000496	0.000501	CcSEcCtD
Acamprosate—Malaise—Doxorubicin—uterine cancer	0.000492	0.000497	CcSEcCtD
Acamprosate—Dry mouth—Epirubicin—uterine cancer	0.000491	0.000496	CcSEcCtD
Acamprosate—Vertigo—Doxorubicin—uterine cancer	0.000491	0.000495	CcSEcCtD
Acamprosate—Syncope—Doxorubicin—uterine cancer	0.00049	0.000494	CcSEcCtD
Acamprosate—Leukopenia—Doxorubicin—uterine cancer	0.000489	0.000493	CcSEcCtD
Acamprosate—Confusional state—Epirubicin—uterine cancer	0.000486	0.00049	CcSEcCtD
Acamprosate—Palpitations—Doxorubicin—uterine cancer	0.000483	0.000487	CcSEcCtD
Acamprosate—Anaphylactic shock—Epirubicin—uterine cancer	0.000482	0.000486	CcSEcCtD
Acamprosate—Loss of consciousness—Doxorubicin—uterine cancer	0.00048	0.000485	CcSEcCtD
Acamprosate—Infection—Epirubicin—uterine cancer	0.000478	0.000483	CcSEcCtD
Acamprosate—Cough—Doxorubicin—uterine cancer	0.000476	0.000481	CcSEcCtD
Acamprosate—Shock—Epirubicin—uterine cancer	0.000474	0.000478	CcSEcCtD
Acamprosate—Convulsion—Doxorubicin—uterine cancer	0.000473	0.000478	CcSEcCtD
Acamprosate—Thrombocytopenia—Epirubicin—uterine cancer	0.000472	0.000476	CcSEcCtD
Acamprosate—Hypertension—Doxorubicin—uterine cancer	0.000471	0.000476	CcSEcCtD
Acamprosate—Tachycardia—Epirubicin—uterine cancer	0.00047	0.000475	CcSEcCtD
Acamprosate—Skin disorder—Epirubicin—uterine cancer	0.000468	0.000472	CcSEcCtD
Acamprosate—Hyperhidrosis—Epirubicin—uterine cancer	0.000466	0.00047	CcSEcCtD
Acamprosate—Chest pain—Doxorubicin—uterine cancer	0.000465	0.000469	CcSEcCtD
Acamprosate—Myalgia—Doxorubicin—uterine cancer	0.000465	0.000469	CcSEcCtD
Acamprosate—Arthralgia—Doxorubicin—uterine cancer	0.000465	0.000469	CcSEcCtD
Acamprosate—Anxiety—Doxorubicin—uterine cancer	0.000463	0.000468	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000462	0.000466	CcSEcCtD
Acamprosate—Discomfort—Doxorubicin—uterine cancer	0.000459	0.000464	CcSEcCtD
Acamprosate—Anorexia—Epirubicin—uterine cancer	0.000459	0.000463	CcSEcCtD
Acamprosate—Dry mouth—Doxorubicin—uterine cancer	0.000455	0.000459	CcSEcCtD
Acamprosate—Hypotension—Epirubicin—uterine cancer	0.00045	0.000454	CcSEcCtD
Acamprosate—Confusional state—Doxorubicin—uterine cancer	0.000449	0.000454	CcSEcCtD
Acamprosate—Anaphylactic shock—Doxorubicin—uterine cancer	0.000446	0.00045	CcSEcCtD
Acamprosate—Infection—Doxorubicin—uterine cancer	0.000443	0.000447	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000439	0.000443	CcSEcCtD
Acamprosate—Shock—Doxorubicin—uterine cancer	0.000438	0.000443	CcSEcCtD
Acamprosate—Thrombocytopenia—Doxorubicin—uterine cancer	0.000436	0.000441	CcSEcCtD
Acamprosate—Insomnia—Epirubicin—uterine cancer	0.000436	0.00044	CcSEcCtD
Acamprosate—Tachycardia—Doxorubicin—uterine cancer	0.000435	0.000439	CcSEcCtD
Acamprosate—Skin disorder—Doxorubicin—uterine cancer	0.000433	0.000437	CcSEcCtD
Acamprosate—Paraesthesia—Epirubicin—uterine cancer	0.000432	0.000437	CcSEcCtD
Acamprosate—Hyperhidrosis—Doxorubicin—uterine cancer	0.000431	0.000435	CcSEcCtD
Acamprosate—Dyspnoea—Epirubicin—uterine cancer	0.000429	0.000434	CcSEcCtD
Acamprosate—Somnolence—Epirubicin—uterine cancer	0.000428	0.000432	CcSEcCtD
Acamprosate—Anorexia—Doxorubicin—uterine cancer	0.000425	0.000429	CcSEcCtD
Acamprosate—Dyspepsia—Epirubicin—uterine cancer	0.000424	0.000428	CcSEcCtD
Acamprosate—Decreased appetite—Epirubicin—uterine cancer	0.000419	0.000423	CcSEcCtD
Acamprosate—Hypotension—Doxorubicin—uterine cancer	0.000416	0.00042	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000416	0.00042	CcSEcCtD
Acamprosate—Constipation—Epirubicin—uterine cancer	0.000412	0.000416	CcSEcCtD
Acamprosate—Pain—Epirubicin—uterine cancer	0.000412	0.000416	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000406	0.00041	CcSEcCtD
Acamprosate—Insomnia—Doxorubicin—uterine cancer	0.000403	0.000407	CcSEcCtD
Acamprosate—Paraesthesia—Doxorubicin—uterine cancer	0.0004	0.000404	CcSEcCtD
Acamprosate—Dyspnoea—Doxorubicin—uterine cancer	0.000397	0.000401	CcSEcCtD
Acamprosate—Feeling abnormal—Epirubicin—uterine cancer	0.000397	0.000401	CcSEcCtD
Acamprosate—Somnolence—Doxorubicin—uterine cancer	0.000396	0.0004	CcSEcCtD
Acamprosate—Gastrointestinal pain—Epirubicin—uterine cancer	0.000394	0.000398	CcSEcCtD
Acamprosate—Dyspepsia—Doxorubicin—uterine cancer	0.000392	0.000396	CcSEcCtD
Acamprosate—Decreased appetite—Doxorubicin—uterine cancer	0.000387	0.000391	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000385	0.000388	CcSEcCtD
Acamprosate—Urticaria—Epirubicin—uterine cancer	0.000383	0.000386	CcSEcCtD
Acamprosate—Constipation—Doxorubicin—uterine cancer	0.000381	0.000385	CcSEcCtD
Acamprosate—Pain—Doxorubicin—uterine cancer	0.000381	0.000385	CcSEcCtD
Acamprosate—Abdominal pain—Epirubicin—uterine cancer	0.000381	0.000384	CcSEcCtD
Acamprosate—Body temperature increased—Epirubicin—uterine cancer	0.000381	0.000384	CcSEcCtD
Acamprosate—Feeling abnormal—Doxorubicin—uterine cancer	0.000367	0.000371	CcSEcCtD
Acamprosate—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000364	0.000368	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—MME—uterine cancer	0.000364	0.0382	CbGpPWpGaD
Acamprosate—Hypersensitivity—Epirubicin—uterine cancer	0.000355	0.000358	CcSEcCtD
Acamprosate—Urticaria—Doxorubicin—uterine cancer	0.000354	0.000357	CcSEcCtD
Acamprosate—Abdominal pain—Doxorubicin—uterine cancer	0.000352	0.000356	CcSEcCtD
Acamprosate—Body temperature increased—Doxorubicin—uterine cancer	0.000352	0.000356	CcSEcCtD
Acamprosate—Asthenia—Epirubicin—uterine cancer	0.000346	0.000349	CcSEcCtD
Acamprosate—Pruritus—Epirubicin—uterine cancer	0.000341	0.000344	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—MME—uterine cancer	0.000339	0.0355	CbGpPWpGaD
Acamprosate—Diarrhoea—Epirubicin—uterine cancer	0.00033	0.000333	CcSEcCtD
Acamprosate—Hypersensitivity—Doxorubicin—uterine cancer	0.000328	0.000331	CcSEcCtD
Acamprosate—Asthenia—Doxorubicin—uterine cancer	0.00032	0.000323	CcSEcCtD
Acamprosate—Dizziness—Epirubicin—uterine cancer	0.000318	0.000322	CcSEcCtD
Acamprosate—Pruritus—Doxorubicin—uterine cancer	0.000315	0.000318	CcSEcCtD
Acamprosate—Vomiting—Epirubicin—uterine cancer	0.000306	0.000309	CcSEcCtD
Acamprosate—Diarrhoea—Doxorubicin—uterine cancer	0.000305	0.000308	CcSEcCtD
Acamprosate—Rash—Epirubicin—uterine cancer	0.000304	0.000307	CcSEcCtD
Acamprosate—Dermatitis—Epirubicin—uterine cancer	0.000303	0.000306	CcSEcCtD
Acamprosate—Headache—Epirubicin—uterine cancer	0.000302	0.000305	CcSEcCtD
Acamprosate—Dizziness—Doxorubicin—uterine cancer	0.000295	0.000298	CcSEcCtD
Acamprosate—Nausea—Epirubicin—uterine cancer	0.000286	0.000289	CcSEcCtD
Acamprosate—Vomiting—Doxorubicin—uterine cancer	0.000283	0.000286	CcSEcCtD
Acamprosate—Rash—Doxorubicin—uterine cancer	0.000281	0.000284	CcSEcCtD
Acamprosate—Dermatitis—Doxorubicin—uterine cancer	0.000281	0.000283	CcSEcCtD
Acamprosate—Headache—Doxorubicin—uterine cancer	0.000279	0.000282	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—MME—uterine cancer	0.000278	0.0291	CbGpPWpGaD
Acamprosate—Nausea—Doxorubicin—uterine cancer	0.000265	0.000267	CcSEcCtD
Acamprosate—GRIN1—Mecp2 and Associated Rett Syndrome—EZH2—uterine cancer	0.000247	0.0258	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—MME—uterine cancer	0.000243	0.0254	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—MME—uterine cancer	0.000236	0.0248	CbGpPWpGaD
Acamprosate—GRIN2C—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—uterine cancer	0.000179	0.0187	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—ABCC9—uterine cancer	0.000173	0.0181	CbGpPWpGaD
Acamprosate—GRIN2D—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—uterine cancer	0.000166	0.0174	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—ABCC9—uterine cancer	0.000161	0.0169	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—PLXNA3—uterine cancer	0.000159	0.0166	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—PLXNA3—uterine cancer	0.000155	0.0162	CbGpPWpGaD
Acamprosate—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—uterine cancer	0.000136	0.0143	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—ABCC9—uterine cancer	0.000132	0.0139	CbGpPWpGaD
Acamprosate—GRIN2B—ErbB4 signaling events—ERBB2—uterine cancer	0.000128	0.0134	CbGpPWpGaD
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—HRAS—uterine cancer	0.000127	0.0133	CbGpPWpGaD
Acamprosate—GRIN1—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—uterine cancer	0.000119	0.0125	CbGpPWpGaD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—uterine cancer	0.000118	0.0124	CbGpPWpGaD
Acamprosate—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—uterine cancer	0.000116	0.0121	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—ABCC9—uterine cancer	0.000115	0.0121	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—PLXNA3—uterine cancer	0.000113	0.0119	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—ABCC9—uterine cancer	0.000112	0.0118	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—PLXNA3—uterine cancer	0.00011	0.0116	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.00011	0.0116	CbGpPWpGaD
Acamprosate—GRIN2A—Reelin signaling pathway—PIK3CA—uterine cancer	0.000108	0.0113	CbGpPWpGaD
Acamprosate—GRIN2C—Post NMDA receptor activation events—HRAS—uterine cancer	0.000105	0.011	CbGpPWpGaD
Acamprosate—GRIN2D—Post NMDA receptor activation events—HRAS—uterine cancer	9.74e-05	0.0102	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—uterine cancer	9.72e-05	0.0102	CbGpPWpGaD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—uterine cancer	9.65e-05	0.0101	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—YWHAE—uterine cancer	9.65e-05	0.0101	CbGpPWpGaD
Acamprosate—GRIN2B—Reelin signaling pathway—PIK3CA—uterine cancer	9.19e-05	0.00962	CbGpPWpGaD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—uterine cancer	8.97e-05	0.00939	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—ESR2—uterine cancer	8.9e-05	0.00933	CbGpPWpGaD
Acamprosate—GRIN2A—Reelin signaling pathway—AKT1—uterine cancer	8.82e-05	0.00924	CbGpPWpGaD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—uterine cancer	8.48e-05	0.00888	CbGpPWpGaD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—uterine cancer	8.26e-05	0.00865	CbGpPWpGaD
Acamprosate—GRIN2A—Post NMDA receptor activation events—HRAS—uterine cancer	8e-05	0.00838	CbGpPWpGaD
Acamprosate—GRIN2B—ErbB4 signaling events—PIK3CA—uterine cancer	7.68e-05	0.00805	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—ABCC9—uterine cancer	7.61e-05	0.00797	CbGpPWpGaD
Acamprosate—GRIN2B—Reelin signaling pathway—AKT1—uterine cancer	7.5e-05	0.00786	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—ABCC9—uterine cancer	7.47e-05	0.00783	CbGpPWpGaD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—uterine cancer	7.37e-05	0.00772	CbGpPWpGaD
Acamprosate—GRIN1—Post NMDA receptor activation events—HRAS—uterine cancer	6.97e-05	0.00731	CbGpPWpGaD
Acamprosate—GRIN2B—Post NMDA receptor activation events—HRAS—uterine cancer	6.8e-05	0.00712	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—ABCC9—uterine cancer	6.53e-05	0.00684	CbGpPWpGaD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—uterine cancer	6.43e-05	0.00673	CbGpPWpGaD
Acamprosate—GRIN1—EPHB-mediated forward signaling—HRAS—uterine cancer	6.43e-05	0.00673	CbGpPWpGaD
Acamprosate—GRIN2B—EPHB-mediated forward signaling—HRAS—uterine cancer	6.26e-05	0.00656	CbGpPWpGaD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—uterine cancer	6.26e-05	0.00656	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKR1B10—uterine cancer	6.13e-05	0.00642	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—TP53—uterine cancer	5.97e-05	0.00625	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—HNF1B—uterine cancer	5.95e-05	0.00624	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CCL2—uterine cancer	5.94e-05	0.00623	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—HNF1B—uterine cancer	5.8e-05	0.00608	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—TP53—uterine cancer	5.55e-05	0.00581	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	5.48e-05	0.00574	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—YWHAE—uterine cancer	5.46e-05	0.00572	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—RNF43—uterine cancer	5.08e-05	0.00532	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—ESR2—uterine cancer	5.04e-05	0.00528	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—CCL2—uterine cancer	4.87e-05	0.0051	CbGpPWpGaD
Acamprosate—GRM5—G alpha (q) signalling events—PIK3CA—uterine cancer	4.84e-05	0.00507	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	4.71e-05	0.00494	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CXCL8—uterine cancer	4.7e-05	0.00492	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—INHBA—uterine cancer	4.65e-05	0.00487	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CDKN1B—uterine cancer	4.59e-05	0.00481	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—VEGFA—uterine cancer	4.58e-05	0.00479	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—TP53—uterine cancer	4.56e-05	0.00477	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—VEGFA—uterine cancer	4.46e-05	0.00467	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	4.33e-05	0.00454	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKR1C1—uterine cancer	4.19e-05	0.00438	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ABCC9—uterine cancer	4.09e-05	0.00429	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ABCC9—uterine cancer	4.02e-05	0.00421	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	4.01e-05	0.0042	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—TP53—uterine cancer	3.98e-05	0.00416	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—TP53—uterine cancer	3.88e-05	0.00406	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—CXCL8—uterine cancer	3.85e-05	0.00403	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	3.76e-05	0.00394	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—CTNNB1—uterine cancer	3.7e-05	0.00387	CbGpPWpGaD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.61e-05	0.00378	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—CTNNB1—uterine cancer	3.6e-05	0.00377	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ABCC9—uterine cancer	3.51e-05	0.00368	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	3.47e-05	0.00363	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.36e-05	0.00352	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—HRAS—uterine cancer	3.31e-05	0.00346	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—HRAS—uterine cancer	3.23e-05	0.00338	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—EP300—uterine cancer	3.22e-05	0.00338	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKR1C3—uterine cancer	3.22e-05	0.00337	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PGR—uterine cancer	3.14e-05	0.00329	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	3.05e-05	0.0032	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MET—uterine cancer	3.02e-05	0.00316	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—YWHAE—uterine cancer	3e-05	0.00314	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MET—uterine cancer	2.95e-05	0.00309	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TP53—uterine cancer	2.88e-05	0.00302	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FBXW7—uterine cancer	2.87e-05	0.00301	CbGpPWpGaD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.76e-05	0.00289	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—HRAS—uterine cancer	2.72e-05	0.00284	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—SMAD3—uterine cancer	2.63e-05	0.00276	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—SMAD3—uterine cancer	2.57e-05	0.00269	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—HRAS—uterine cancer	2.52e-05	0.00264	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—STK11—uterine cancer	2.51e-05	0.00263	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—CCL2—uterine cancer	2.5e-05	0.00262	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—CTNNB1—uterine cancer	2.44e-05	0.00255	CbGpPWpGaD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.41e-05	0.00252	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—HRAS—uterine cancer	2.35e-05	0.00246	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SOCS3—uterine cancer	2.35e-05	0.00246	CbGpPWpGaD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.34e-05	0.00246	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—HRAS—uterine cancer	2.29e-05	0.0024	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CDKN2B—uterine cancer	2.25e-05	0.00236	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—ERBB2—uterine cancer	2.21e-05	0.00231	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IGF1R—uterine cancer	2.19e-05	0.00229	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—CXCL8—uterine cancer	2.18e-05	0.00228	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MET—uterine cancer	2.16e-05	0.00226	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—ERBB2—uterine cancer	2.15e-05	0.00226	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	2.13e-05	0.00223	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MET—uterine cancer	2.1e-05	0.0022	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—HRAS—uterine cancer	2.08e-05	0.00218	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—AKT1—uterine cancer	2.08e-05	0.00217	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—HRAS—uterine cancer	2.07e-05	0.00217	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SMAD3—uterine cancer	2.05e-05	0.00215	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—AKT1—uterine cancer	2.02e-05	0.00212	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—CXCL8—uterine cancer	1.98e-05	0.00207	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	1.96e-05	0.00206	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FGFR2—uterine cancer	1.96e-05	0.00205	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—HRAS—uterine cancer	1.93e-05	0.00203	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—EP300—uterine cancer	1.83e-05	0.00191	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—HRAS—uterine cancer	1.81e-05	0.00189	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—HRAS—uterine cancer	1.76e-05	0.00185	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	1.73e-05	0.00181	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—VEGFA—uterine cancer	1.7e-05	0.00178	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—NRAS—uterine cancer	1.68e-05	0.00176	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ESR1—uterine cancer	1.68e-05	0.00176	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—VEGFA—uterine cancer	1.66e-05	0.00174	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—NRAS—uterine cancer	1.64e-05	0.00172	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—HRAS—uterine cancer	1.59e-05	0.00166	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	1.59e-05	0.00166	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—NRAS—uterine cancer	1.58e-05	0.00166	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—ERBB2—uterine cancer	1.58e-05	0.00165	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	1.56e-05	0.00163	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—HRAS—uterine cancer	1.55e-05	0.00163	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—ERBB2—uterine cancer	1.54e-05	0.00161	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CCL2—uterine cancer	1.48e-05	0.00155	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—KRAS—uterine cancer	1.45e-05	0.00151	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—KRAS—uterine cancer	1.41e-05	0.00148	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—HRAS—uterine cancer	1.39e-05	0.00145	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—PIK3CA—uterine cancer	1.38e-05	0.00145	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CTNNB1—uterine cancer	1.38e-05	0.00144	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—AKT1—uterine cancer	1.37e-05	0.00143	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—KRAS—uterine cancer	1.36e-05	0.00143	CbGpPWpGaD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	1.36e-05	0.00143	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—HRAS—uterine cancer	1.35e-05	0.00141	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CTNNB1—uterine cancer	1.34e-05	0.00141	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—EP300—uterine cancer	1.28e-05	0.00134	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PIK3CA—uterine cancer	1.25e-05	0.00131	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—EP300—uterine cancer	1.25e-05	0.00131	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ERBB2—uterine cancer	1.23e-05	0.00129	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—HRAS—uterine cancer	1.23e-05	0.00129	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—VEGFA—uterine cancer	1.21e-05	0.00127	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—NRAS—uterine cancer	1.2e-05	0.00126	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—HRAS—uterine cancer	1.2e-05	0.00126	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—HRAS—uterine cancer	1.19e-05	0.00125	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—VEGFA—uterine cancer	1.18e-05	0.00124	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—HRAS—uterine cancer	1.17e-05	0.00123	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—NRAS—uterine cancer	1.17e-05	0.00122	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CXCL8—uterine cancer	1.17e-05	0.00122	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—HRAS—uterine cancer	1.16e-05	0.00121	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CDKN1B—uterine cancer	1.14e-05	0.00119	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—AKT1—uterine cancer	1.13e-05	0.00118	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CTNNB1—uterine cancer	1.08e-05	0.00113	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTEN—uterine cancer	1.05e-05	0.0011	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—KRAS—uterine cancer	1.03e-05	0.00108	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—HRAS—uterine cancer	1.02e-05	0.00107	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—AKT1—uterine cancer	1.02e-05	0.00107	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—KRAS—uterine cancer	1.01e-05	0.00105	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EP300—uterine cancer	1e-05	0.00105	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—VEGFA—uterine cancer	9.48e-06	0.000993	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NRAS—uterine cancer	9.36e-06	0.000981	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—HRAS—uterine cancer	9.14e-06	0.000957	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—HRAS—uterine cancer	8.98e-06	0.00094	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—HRAS—uterine cancer	8.77e-06	0.000919	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—HRAS—uterine cancer	8.55e-06	0.000896	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KRAS—uterine cancer	8.06e-06	0.000844	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—HRAS—uterine cancer	7.85e-06	0.000822	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—AKT1—uterine cancer	7.75e-06	0.000811	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—AKT1—uterine cancer	7.55e-06	0.000791	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PIK3CA—uterine cancer	7.4e-06	0.000775	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TP53—uterine cancer	7.16e-06	0.00075	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HRAS—uterine cancer	6.85e-06	0.000717	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKT1—uterine cancer	6.05e-06	0.000633	CbGpPWpGaD
